financetom
Business
financetom
/
Business
/
HIL shares hit 52-week high on robust Q4 earnings; roofing biz gains momentum, says CEO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
HIL shares hit 52-week high on robust Q4 earnings; roofing biz gains momentum, says CEO
May 17, 2021 5:09 AM

Shares of HIL Ltd jumped over 9 percent to hit a 52-week high of Rs 4,090 on the BSE after the company reported strong earnings for the fourth quarter of fiscal 2021.

The building materials and solutions company posted a standalone net profit of Rs 40.55 crore in Q4FY21 as compared to a net profit of Rs 8.07 crore in the year-ago period. Its revenue from operations increased 51.84 percent to Rs 452.06 crore from Rs 297.72 crore, YoY.

The company’s sales in April were good, while it will continue the cost control measures going ahead, HIL Managing Director and CEO, Dhirup Roy Choudhary told CNBC-TV18.

“On the topline we would assume that we will try to maintain the growth prospect and on the bottom-line as well we are confident that we will be able to strive hard on the roofing side. Building material at the moment is going through a bit of a cramp because of unavailability of labour,” Choudhary said.

HIL has gained market share by 1 percent and its market share in the roofing business currently stands at 21 percent, he added.

“I am confident that roofing is going to take a sharper benefit from the down to the last sales connect that they have been able to make last year. We have been able to acquire about 1,200 new counters and we have gained market share by 1 percent over the earlier years. Our market share stands at 21 percent on roofing and that I think we should continue,” Choudhary said.

During the quarter, HIL took price hikes that offset the material cost price, Choudhary said, reiterating to continue with cost-saving measures.

On the impact of lockdown, Choudhary said, “As we speak at the moment all or factories are running, even in Europe the factories are running, all the plants are running. The godowns are absolutely well furnished and working well. Sales are doing well, April has been a good month for us and May at the moment is slightly difficult, but we are confident that we will find our way through the digital model.”

For full interview, watch the accompanying video...

(Edited by : Ankit Gohel)

First Published:May 17, 2021 2:09 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BioCardia Receives Patent for Morph DNA Transseptal Delivery
BioCardia Receives Patent for Morph DNA Transseptal Delivery
Jul 17, 2024
08:45 AM EDT, 07/17/2024 (MT Newswires) -- BioCardia ( BCDA ) said Wednesday that it was granted a patent for its method for transseptal access to the heart using a steerable catheter based on the company's Morph DNA technology. The patent issued by the US Patent Office protects the company's products through 2035, BioCardia ( BCDA ) said. BioCardia's (...
Correction: Prologis Q2 Core Funds From Operations, Revenue Falls; Updates 2024 Core FFO Outlook
Correction: Prologis Q2 Core Funds From Operations, Revenue Falls; Updates 2024 Core FFO Outlook
Jul 17, 2024
08:32 AM EDT, 07/17/2024 (MT Newswires) -- Prologis ( PLD ) reported Q2 core funds from operations Wednesday of $1.34 per diluted share, compared with $1.83 a year earlier. Analysts polled by Capital IQ expected $1.07. Total revenue for the quarter ended June 30 was $2.01 billion, down from about $2.45 billion a year earlier. Analysts surveyed by Capital IQ...
Northern Trust's profit surges on fee income boost, accounting gain
Northern Trust's profit surges on fee income boost, accounting gain
Jul 17, 2024
(Reuters) - Asset and wealth manager Northern Trust ( NTRS ) posted a more than two-fold jump in second-quarter profit on Wednesday, thanks to higher fee income and an accounting gain of $878.4 million from a stock exchange deal with Visa. Hopes of a soft landing for the U.S. economy and investor frenzy around artificial intelligence have lifted the stock...
Immutep Receives Dutch Regulatory Approval to Begin Human Testing of Potential Autoimmune Treatment
Immutep Receives Dutch Regulatory Approval to Begin Human Testing of Potential Autoimmune Treatment
Jul 17, 2024
08:45 AM EDT, 07/17/2024 (MT Newswires) -- Immutep ( IMMP ) said Wednesday it has received regulatory clearance from the Netherlands' ethics authority to begin human testing of its IMP761 potential autoimmune disease treatment. Immutep ( IMMP ) describes IMP761 as a LAG-3 agonist antibody to potentially treat rheumatoid arthritis, type 1 diabetes, and multiple sclerosis, among other autoimmune diseases....
Copyright 2023-2026 - www.financetom.com All Rights Reserved